PT3789389T - Forma cristalina de (s)-n-[5-[1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil)etil]-4,6-dioxo-5,6-di-hidro-4h-tieno[3,4-c]pirrol-1-il]acetamida - Google Patents

Forma cristalina de (s)-n-[5-[1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil)etil]-4,6-dioxo-5,6-di-hidro-4h-tieno[3,4-c]pirrol-1-il]acetamida

Info

Publication number
PT3789389T
PT3789389T PT197971435T PT19797143T PT3789389T PT 3789389 T PT3789389 T PT 3789389T PT 197971435 T PT197971435 T PT 197971435T PT 19797143 T PT19797143 T PT 19797143T PT 3789389 T PT3789389 T PT 3789389T
Authority
PT
Portugal
Prior art keywords
crystal form
thiophene derivative
thiophene
derivative
crystal
Prior art date
Application number
PT197971435T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Tianjin Hemay Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Hemay Pharmaceutical Co Ltd filed Critical Tianjin Hemay Pharmaceutical Co Ltd
Publication of PT3789389T publication Critical patent/PT3789389T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
PT197971435T 2018-05-02 2019-04-30 Forma cristalina de (s)-n-[5-[1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil)etil]-4,6-dioxo-5,6-di-hidro-4h-tieno[3,4-c]pirrol-1-il]acetamida PT3789389T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810407741 2018-05-02

Publications (1)

Publication Number Publication Date
PT3789389T true PT3789389T (pt) 2025-12-17

Family

ID=68386284

Family Applications (1)

Application Number Title Priority Date Filing Date
PT197971435T PT3789389T (pt) 2018-05-02 2019-04-30 Forma cristalina de (s)-n-[5-[1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil)etil]-4,6-dioxo-5,6-di-hidro-4h-tieno[3,4-c]pirrol-1-il]acetamida

Country Status (14)

Country Link
US (4) US11396518B2 (enExample)
EP (5) EP3800190A4 (enExample)
JP (5) JP7481263B2 (enExample)
KR (4) KR102686835B1 (enExample)
CN (7) CN116947878B (enExample)
AU (4) AU2019262282B2 (enExample)
BR (4) BR112020021976A2 (enExample)
CA (4) CA3213055A1 (enExample)
DK (1) DK3789389T3 (enExample)
ES (1) ES3047059T3 (enExample)
FI (1) FI3789389T3 (enExample)
PL (1) PL3789389T3 (enExample)
PT (1) PT3789389T (enExample)
WO (4) WO2019210869A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3789389T3 (pl) * 2018-05-02 2026-03-16 Tianjin Hemay Pharmaceutical Co., Ltd. Postać krystaliczna (s)-n-[5-[1-(3-etoksy-4-metoksyfenylo)-2-(metylosulfonylo)etylo]-4,6-diokso-5,6-dihydro-4h-tieno[3,4-c]pirol-1-ilo]acetamidu
WO2025103428A1 (zh) * 2023-11-14 2025-05-22 赣州和美药业股份有限公司 中重度斑块型银屑病的治疗

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
AU2003243153A1 (en) * 2002-04-23 2003-11-10 Dr. Reddy's Laboratories Limited Novel crystalline polymorph form-vi of olanzapine and a process for preparation thereof
CN101186612B (zh) 2006-11-15 2012-10-03 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的吡咯啉衍生物及其制备和应用
KR101514866B1 (ko) 2009-05-14 2015-04-24 티안진 헤메이 바이오-텍 컴퍼니 리미티드 티오펜 유도체
US8946474B2 (en) * 2010-06-30 2015-02-03 Leo Pharma A/S Polymorphic form of a calcimimetic compound
CN105793251B (zh) * 2013-12-05 2018-10-12 豪夫迈·罗氏有限公司 具有亲电子官能性的杂芳基吡啶酮和氮杂-吡啶酮化合物
WO2016010178A1 (ko) * 2014-07-18 2016-01-21 주식회사 녹십자 5-클로로-ｎ-({(5ｓ)-2-옥소-3-[4-(5,6-디하이드로-4h-[1,2,4]트리아진-1-일)페닐]-1,3-옥사졸리딘-5-일}메틸)티오펜-2-카르복사미드 메탄설폰산염의 신규 결정형 및 이를 포함하는 약학 조성물
EP3144393A1 (en) * 2015-09-18 2017-03-22 LEK Pharmaceuticals d.d. A synthetic pathway towards apremilast
CN107417626B (zh) * 2016-05-23 2020-01-24 江苏奥赛康药业有限公司 一种2-氨基嘧啶类化合物的多晶型形式
CN107474057B (zh) * 2016-06-07 2021-03-12 天津药物研究院有限公司 (5-(2-腈基苄基)-4,5,6,7-四氢噻吩并[3,2-c]吡啶-2-基)乙酸酯盐酸盐的晶型及其制备方法和用途
US10570147B2 (en) * 2017-06-13 2020-02-25 Biotheryx, Inc. Bicyclic compounds and methods of use
EP3644860B1 (en) * 2017-06-30 2024-05-08 Trophy An extra oral dental imaging apparatus with patient positioning accessory detection
PL3789389T3 (pl) 2018-05-02 2026-03-16 Tianjin Hemay Pharmaceutical Co., Ltd. Postać krystaliczna (s)-n-[5-[1-(3-etoksy-4-metoksyfenylo)-2-(metylosulfonylo)etylo]-4,6-diokso-5,6-dihydro-4h-tieno[3,4-c]pirol-1-ilo]acetamidu

Also Published As

Publication number Publication date
EP4335515A2 (en) 2024-03-13
US11396518B2 (en) 2022-07-26
DK3789389T3 (da) 2025-11-10
AU2019263865B2 (en) 2022-01-27
JP2024026251A (ja) 2024-02-28
FI3789389T3 (fi) 2025-11-19
JP2021523935A (ja) 2021-09-09
JP2021523891A (ja) 2021-09-09
KR20210025001A (ko) 2021-03-08
EP3789388B1 (en) 2024-01-24
JP7542523B2 (ja) 2024-08-30
AU2019262282A1 (en) 2020-11-12
EP3800190A4 (en) 2022-01-26
KR20210022557A (ko) 2021-03-03
CA3098927C (en) 2023-10-03
CA3099072A1 (en) 2019-11-07
KR102701245B1 (ko) 2024-08-30
EP3789387B1 (en) 2024-02-28
WO2019210864A1 (zh) 2019-11-07
ES3047059T3 (en) 2025-12-03
JP2021523890A (ja) 2021-09-09
BR112020022190A2 (pt) 2021-02-02
EP3789389A4 (en) 2022-01-26
EP3800190A1 (en) 2021-04-07
CN110437251B (zh) 2023-07-21
US12180222B2 (en) 2024-12-31
CN116854705A (zh) 2023-10-10
CA3098931C (en) 2023-10-24
EP3789389A1 (en) 2021-03-10
PL3789389T3 (pl) 2026-03-16
CA3099071A1 (en) 2019-11-07
US20210380600A1 (en) 2021-12-09
US20210139498A1 (en) 2021-05-13
CN116836178A (zh) 2023-10-03
EP3789387A4 (en) 2021-06-30
BR112020021945A2 (pt) 2021-01-26
WO2019210869A1 (zh) 2019-11-07
BR112020021976A2 (pt) 2021-01-26
JP7481263B2 (ja) 2024-05-10
US12227514B2 (en) 2025-02-18
WO2019210865A1 (zh) 2019-11-07
EP4335515A3 (en) 2024-07-03
JP7477459B2 (ja) 2024-05-01
KR20210022556A (ko) 2021-03-03
AU2019262286B2 (en) 2022-08-11
JP2021522348A (ja) 2021-08-30
US20210230181A1 (en) 2021-07-29
EP3789388A4 (en) 2021-06-09
CA3098931A1 (en) 2019-11-07
WO2019210867A1 (zh) 2019-11-07
AU2019263865A1 (en) 2020-12-24
CN110437250B (zh) 2023-06-23
CN110437249B (zh) 2023-07-21
US20210238191A1 (en) 2021-08-05
CN116947878A (zh) 2023-10-27
CN116854705B (zh) 2026-06-19
CN116947878B (zh) 2026-06-19
KR20210025000A (ko) 2021-03-08
EP3789388A1 (en) 2021-03-10
US11274104B2 (en) 2022-03-15
EP3789389B1 (en) 2025-10-08
CN116813637A (zh) 2023-09-29
CN110437251A (zh) 2019-11-12
AU2019262282B2 (en) 2022-04-28
AU2019262284A1 (en) 2020-12-24
CA3098927A1 (en) 2019-11-07
KR102839924B1 (ko) 2025-07-29
EP3789387A1 (en) 2021-03-10
CN110437250A (zh) 2019-11-12
CA3213055A1 (en) 2019-11-07
CN110437249A (zh) 2019-11-12
KR102686835B1 (ko) 2024-07-22
BR112020022186A2 (pt) 2021-02-02
AU2019262286A1 (en) 2020-11-12

Similar Documents

Publication Publication Date Title
IL279468A (en) Crystallographic modifications of odeviccibat
IL272888A (en) Uses of piperidinyl-indole derivatives
IL271028A (en) Inhibition of crystal growth of roflumilest
PT3601239T (pt) Novos derivados heterocíclicos úteis como inibidores de shp2
SMT202400053T1 (it) Derivati deuterati del lanifibranor
SG11202106378VA (en) Modulators of hsd17b13 expression
SG11202102636UA (en) Modulators of pnpla3 expression
IL276592A (en) History of Subtirum
IL272697A (en) A polymorphic form of TG02
IL273237A (en) Novel heterocyclic compounds as MGLUR7 modulators
PL3636640T3 (pl) Kryształ heterocyklidenowej pochodnej acetamidu
PL3532457T3 (pl) Postacie krystaliczne hydroksynorketaminy
IL270961A (en) Crystalline form of N-butyldeoxygalactonogirimycin
EP3789388A4 (en) THIOPHENE DERIVATIVE CRYSTALLINE FORM
PT3395819T (pt) Forma cristalina de derivado de aminopirano substituído
ZA202100484B (en) Crystal of benzoxazole derivative
SG11202105136WA (en) Application of chidamide
GB201807417D0 (en) Improvements to open display refridgerators
GB201807418D0 (en) Improvements to open display refridgerators
SMT202100726T1 (it) Nuovi composti
PT3901141T (pt) Nova forma de isoquinolinossulfonamida
IL270937A (en) Crystalline forms of saltalicib
GB201721858D0 (en) Update
GB201714440D0 (en) By contract of employment